Search Results - "Zhang, Shannon S"

Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis by Zhu, Viola W., Zhao, Joseph J., Gao, Yanfei, Syn, Nicholas L., Zhang, Shannon S., Ou, Sai-Hong Ignatius, Bauer, Kenneth A., Nagasaka, Misako

“…•ALK+ and ROS1+ NSCLC patients have increased risk of thromboembolism.•The risk of thromboembolism is statistically higher in ROS1+ than ALK+ NSCLC…”
Get full text

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing by Nagasaka, Misako, Zhang, Shannon S, Baca, Yasmine, Xiu, Joanne, Nieva, Jorge, Vanderwalde, Ari, Swensen, Jeffrey J, Spetzler, David, Korn, Wolfgang Michael, Raez, Luis E, Liu, Stephen V, Ou, Sai-Hong Ignatius

“…Abstract Background Two ROS1 tyrosine kinase inhibitors have been approved for  ROS1  fusion positive ( ROS1 +) non-small cell lung cancer (NSCLC) tumors. We…”
Get full text

Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides by Shinchi, Hiroyuki, Crain, Brian, Yao, Shiyin, Chan, Michael, Zhang, Shannon S, Ahmadiiveli, Alast, Suda, Yasuo, Hayashi, Tomoko, Cottam, Howard B, Carson, Dennis A

“…Toll-like receptors (TLRs) in the innate immune system recognize specific pathogen-associated molecular patterns derived from microbes. Synthetic small…”
Get full text

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors by Zhang, Shannon S., Ou, Sai-Hong Ignatius

Get full text

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature by Zhang, Shannon S., Lee, Jessica K., Tukachinsky, Hanna, Schrock, Alexa B., Nagasaka, Misako, Ou, Sai-Hong Ignatius

“…Germline CHEK2 mutations are rare and have not been associated with increased risk of NSCLC. We identified two sequential primary NSCLCs harboring distinct…”
Get full text

In Response to Dr. Steven Sorscher by Zhang, Shannon S., Schrock, Alexa B., Nagasaka, Misako, Ou, Sai-Hong Ignatius

Get full text

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report by Thummalapalli, Rohit, Choudhury, Noura J., Ehrich, Fiona, Beardslee, Tyler, Brazel, Danielle, Zhang, Shannon S., Merchant, Shelby, Chen, Monica F., Heller, Glenn, Ramalingam, Suresh S., Ou, Sai-Hong Ignatius, Mileham, Kathryn F., Riely, Gregory J.

“…Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events…”
Get full text

Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing by Ou, Sai-Hong Ignatius, Xiu, Joanne, Nagasaka, Misako, Xia, Bing, Zhang, Shannon S., Zhang, Qing, Swensen, Jeffrey J., Spetzler, David, Korn, Wolfgang Michael, Zhu, Viola W., Liu, Stephen V.

“…A novel CD74-NRG2α fusion has recently been identified in NSCLC. We surveyed a large tumor database comprehensively profiled by whole transcriptome sequencing…”
Get full text

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC by Zhang, Shannon S., Nagasaka, Misako, Zhu, Viola W., Ou, Sai-Hong Ignatius

“…•A figure showing the structural domains of the major “numbered” EML4-ALK variants.•A pie-chart showing the distribution of 13 EML4-ALK variants.•A figure…”
Get full text

Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis by Triphuridet, Natthaya, Zhang, Shannon S, Nagasaka, Misako, Gao, Yanfei, Zhao, Joseph J, Syn, Nicholas L, Hanaoka, Takaomi, Ou, Sai-Hong Ignatius, Shum, Elaine

“…Lung cancer in never-smokers is the major cancer cause of death globally. We compared the efficacy of low-dose computed tomography (LDCT) lung cancer screening…”
Get more information

Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib by Zhu, Viola W, Zhang, Shannon S, Zhang, Jian, Swensen, Jeffrey, Xiu, Joanne, Ou, Sai-Hong Ignatius

Get more information

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer by Sato-Kaneko, Fumi, Yao, Shiyin, Ahmadi, Alast, Zhang, Shannon S, Hosoya, Tadashi, Kaneda, Megan M, Varner, Judith A, Pu, Minya, Messer, Karen S, Guiducci, Cristiana, Coffman, Robert L, Kitaura, Kazutaka, Matsutani, Takaji, Suzuki, Ryuji, Carson, Dennis A, Hayashi, Tomoko, Cohen, Ezra Ew

“…Checkpoint inhibitors have demonstrated efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the majority…”
Get full text

Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis by Nagasaka, Misako, Balmanoukian, Ani S., Madison, Russell, Zhang, Shannon S., Klempner, Samuel J., Ou, Sai-Hong Ignatius

“…•First detaled patient case report of amivantamab monotherapy active against EGFR triple mutation (L858R/T790M/G796S) in cis.•Symptomatic, biochemical, and…”
Get full text

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations by Zhang, Shannon S, Zhu, Viola W

“…The EGFR exon 20 insertion (EGFRex20ins) mutations are the third most common EGFR mutations seen in non-small cell lung cancer (NSCLC). More than 50 variants…”
Get full text

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs? by Zhang, Shannon S, Ou, Sai-hong Ignatius

“…Osimertinib, a third-generation (3G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is now considered the standard of care for the…”
Get full text

Acquired Resistance to KRAS G12C Inhibition in Cancer by Awad, Mark M, Liu, Shengwu, Rybkin, Igor I, Arbour, Kathryn C, Dilly, Julien, Zhu, Viola W, Johnson, Melissa L, Heist, Rebecca S, Patil, Tejas, Riely, Gregory J, Jacobson, Joseph O, Yang, Xiaoping, Persky, Nicole S, Root, David E, Lowder, Kristen E, Feng, Hanrong, Zhang, Shannon S, Haigis, Kevin M, Hung, Yin P, Sholl, Lynette M, Wolpin, Brian M, Wiese, Julie, Christiansen, Jason, Lee, Jessica, Schrock, Alexa B, Lim, Lee P, Garg, Kavita, Li, Mark, Engstrom, Lars D, Waters, Laura, Lawson, J David, Olson, Peter, Lito, Piro, Ou, Sai-Hong I, Christensen, James G, Jänne, Pasi A, Aguirre, Andrew J

“…Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid…”
Get full text

Spotlight on Sotorasib (AMG 510) for KRA[S.sup.G12C] Positive Non-Small Cell Lung Cancer by Zhang, Shannon S, Nagasaka, Misako

“…Mutations in codon 12 of KRAS have been identified in 13% of non-small cell lung cancer patients. Developing targeted therapies against KRA[S.sup.G12C]…”
Get full text

CodeBreak 200: Sotorasib Has Not Broken the KRA[S.sup.G12C] Enigma Code by Zhang, Shannon S, Lee, Alexandria, Nagasaka, Misako

“…Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has…”
Get full text

CodeBreak 200: Sotorasib Has Not Broken the KRAS G12C Enigma Code by Zhang, Shannon S, Lee, Alexandria, Nagasaka, Misako

“…Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has…”
Get full text

Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer by Zhang, Shannon S, Nagasaka, Misako

Get full text